TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
TransCode Therapeutics, Inc. recently announced initiation of its Phase 1 multicenter, open-label, clinical study of its lead therapeutic candidate, TTX-MC138. Two clinical trial sites have been activated with patient enrollment expected to begin during the current quarter. TransCode may activate a total of up to five clinical trial sites, all of which are expected to be activated this quarter.
The Phase 1 clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138 in patients with a variety of metastatic solid cancer. It may provide early evidence of TTX-MC138 clinical activity. The trial comprises an initial dose-escalation phase followed by a dose-expansion phase. The primary objective of the dose-escalation phase is to evaluate the safety and tolerability of escalating dose levels of TTX-MC138. In the dose-expansion phase, the safety, tolerability and anti-tumor activity of TTX-MC138 will be further evaluated in certain tumor types selected based on preliminary results from the dose-escalation phase.
“We are thrilled to have garnered such high interest in TTX-MC138 from eminent oncologists working in some of the most respected clinical trial sites in the country,” said Sue Duggan, Senior Vice President, Operations, at TransCode. “Advancing breakthrough RNA therapeutics science in the clinic is our primary goal as a biotechnology company at the cusp of innovative technology.”
Active and recruiting sites can be found at:
https://clinicaltrials.gov/study/NCT06260774?spons=transcode&rank=1.
TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Total Page Views: 511
